OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED

All amounts in this press release are in Canadian dollars.

QUÉBEC CITY, Nov. 28, 2023 /CNW/ - OpSens Inc. ("OpSens" or the "Corporation") (TSX:OPS.TO) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, is pleased to announce that in connection with the previously announced acquisition by Haemonetics Corporation ("Haemonetics") (NYSE:HAE) of all of the issued and outstanding common shares in the capital of OpSens (the "Shares") for $2.90 in cash per Share, pursuant to a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (Québec), the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act") and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act (Canada) R.S.C., 1985, c. 28 (1^st Supp.), as amended (the "ICA") has expired without any such notice having been sent.